Examination of EXOSC4 as a new prognostic marker and a novel therapeutic avenue in lung adenocarcinoma


Autoria(s): O'Byrne, K.; Paquet, N.; Box, J.K.; Adams, M.; Richard, D.
Data(s)

2016

Resumo

Although prevention and early detection of the disease greatly improved over the past few years, lung cancer remains the leading cause of cancer deaths. In order to be able to treat a larger population, we are in urgent need for novel treatments. While it is known that DNA repair genes play a major role in the oncogenic transformation, they also represent a weakness of cancers that constitute a therapeutic opportunity. To identify novel DNA repair genes implicated in Lung cancers, we conducted an in silico investigation to identify genes co-regulated with two DNA repair factors, BRCA2 and hSSB1. This approach allowed for the identification of EXOSC4, a component of the RNA Exosome machinery, as a potential factor involved in the maintenance of genome stability and that is deregulated in lung cancer.

Identificador

http://eprints.qut.edu.au/95258/

Publicador

Elsevier

Relação

DOI:10.1016/S1556-0864(16)30131-9

O'Byrne, K., Paquet, N., Box, J.K., Adams, M., & Richard, D. (2016) Examination of EXOSC4 as a new prognostic marker and a novel therapeutic avenue in lung adenocarcinoma. In European Lung Cancer Conference (ELCC 2016), 13 - 16 April 2016, Geneva, Switzerland.

Fonte

School of Biomedical Sciences; Faculty of Health; Institute of Health and Biomedical Innovation

Tipo

Conference Item